Avoiding Treatment in the Hospital With Furoscix for the Management of Congestion in Heart Failure - A Pilot Study

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

April 18, 2022

Study Completion Date

April 18, 2022

Conditions
Heart Failure
Interventions
COMBINATION_PRODUCT

Furoscix Infusor

Furoscix Infusor, a drug-device combination product for subcutaneous delivery of Furoscix, buffered furosemide injection, 8 mg/mL (total dose = 80 mg dose) administered subcutaneously for 5 hours.

Trial Locations (18)

10029

Icahn School of Medicine at Mount Sinai, New York

17602

Lancaster General Hospital, Lancaster

27455

Cone Health Medical Group, Greensboro

30901

University Hospital - Augusta, Augusta

32256

First Coast Cardiovascular Institute, Jacksonville

32501

Cardiology Consultants, Pensacola

32611

University of Florida, Gainesville

33012

Elite Cardiac Research, Hialeah

33541

Aventura Clinical Research, LLC, Aventura

33612

James A. Haley Veerans Hospital, Tampa

35801

The Heart Center Research, LLC, Huntsville

36532

Heart Group of Eastern Shore, Fairhope

48197

Michigan Heart, Ypsilanti

53792

University of Wisconsin, Madison

60515

Advocate Health and Hospitals, Downers Grove

61606

UnityPoint Health - Methodist Hospital, Peoria

63136

St. Louis Heart and Vascular, St Louis

06102

Hartford Hospital, Hartford

All Listed Sponsors
lead

scPharmaceuticals, Inc.

INDUSTRY